Fractalkine as an important target of aspirin in the prevention of atherogenesis : Editorial to: "Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice" by H. Liu et al.
Noels
Heidi
H
Weber
Christian
C
D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D054428:Chemokine CX3CL1 / Q000378:metabolism*; D018925:Chemokines / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009000:Monocytes / Q000378:metabolism / Q000473:pathology; D019707:Receptors, Chemokine / Q000378:metabolism
D001057:Apolipoproteins E; D054428:Chemokine CX3CL1; D018925:Chemokines; C515539:Cx3cl1 protein, mouse; D016861:Cyclooxygenase Inhibitors; D019707:Receptors, Chemokine; D001241:Aspirin